Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1001 Results for "
attenuation
" in MedChemExpress (MCE) Product Catalog:
Products (1001)
1001 Results for "attenuation" in MCE Product Catalog:
Cat. No.: HY-P11291B
Target:
Research Areas:
NNC0165-1273 acetate is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 acetate blocks Ghrelin-induced cFos expression. NNC0165-1273 acetate reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 acetate reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 acetate can be used in studies related to diet-induced obesity .
Cat. No.: HY-P4121
CAS No.: 1898254-09-5
Target:
Research Areas:
Cat. No.: HY-P5917
CAS No.: 1373890-79-9
Synonyms: Vaejovis mexicanus peptide 24
Target:
Research Areas:
Cat. No.: HY-P5917A
Synonyms: Vaejovis mexicanus peptide 24 TFA
Target:
Research Areas:
Cat. No.: HY-P991740
Target:
Research Areas:
Cat. No.: HY-P991752
Target:
Research Areas:
Cat. No.: HY-W615446
CAS No.: 158890-32-5
Research Areas:
GSTO1-IN-3 is a potent GSTO1-1 inhibitor with an IC50 of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC50 > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .
Cat. No.: HY-W747071
CAS No.: 71781-63-0
Research Areas:
Glycoursodeoxycholic acid 3-sulfate disodium is a glycine-conjugated sulfated bile acid 3-sulfate, which is produced by SULT2A1-mediated sulfation of glycoursodeoxycholic acid (HY-N1424) in the liver. Glycoursodeoxycholic acid 3-sulfate disodium attenuates the anti-inflammatory effect of glycoursodeoxycholic acid and impairs the inhibitory effect on the IL-17 and NF-κB signaling pathways. Glycoursodeoxycholic acid 3-sulfate disodium shows a significant correlation with aortic flow velocity and BNP in patients with aortic stenosis. Glycoursodeoxycholic acid 3-sulfate disodium is mainly used in related studies such as quantitative analysis, quality control and biochemical experiments; it often serves as a reagent for metabolomics analysis and can also be applied to research related to aortic stenosis .
Cat. No.: HY-100742AR
CAS No.: 2003234-63-5
Research Areas:
(R)-GNE-140 (Standard) is the analytical standard of (R)-GNE-140 (HY-100742A). This product is intended for research and analytical applications. (R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
Research Areas:
NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
Research Areas:
Benarthin is an orally active Pyroglutamyl peptidase inhibitor, THY1 inhibitor (with a Kd value of 5.13e-08 M) and competitive PGP-1 inhibitor (Ki = 1.2 µM). Benarthin is isolated from the culture broth of Streptomyces xanthophaeus MJ244-SF1. Benarthin disrupts the THY1-SFRP1 interaction, inhibits the activation of the GSK3α/β-β-catenin pathway, and reduces the upregulation of FASLG. Benarthin attenuates urothelial anoikis and reduces cell Apoptosis. Benarthin possesses iron-chelating activity. Benarthin maintains urothelial barrier integrity and blocks the pathological cascade of renal interstitial fibroblasts induced by HAP stimulation. Benarthin can be used in studies related to kidney stones .
Cat. No.: HY-118998
CAS No.: 1603845-42-6
TX2-121-1 is a bifunctional hydrophobic tag Her3 degrader and also a Her3 inhibitor with an IC50 of 49 nM. TX2-121-1 covalently binds to Cys721 of Her3, induces Her3 degradation via the Hsp70/Hsp90-assisted proteasomal pathway, interferes with the heterodimerization of Her3 with Her2/c-Met, and attenuates downstream Erk/Akt signaling, thereby inhibiting Her3-dependent cancer cell growth. TX2-121-1 can be used for the research of non-small cell lung cancer, ovarian cancer and Her3-driven breast cancer .
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer .
Cat. No.: HY-155297
CAS No.: 55248-23-2
Synonyms: FLA-136
Target:
Research Areas:
Nebidrazine is a centrally-acting hypotensive agent compared to clonidine, demonstrating weaker cardiovascular effects in rats. It induces dose-dependent hypotension and bradycardia when administered intracerebroventricularly (i.c.v.), with significantly lower sedative potential than clonidine in conscious rats. Yohimbine attenuates the cardiovascular effects of both Nebidrazine and clonidine, suggesting involvement of central alpha-autoreceptors sensitive to yohimbine. Unlike clonidine, Nebidrazine does not affect peripheral alpha-adrenoceptors in pithed rats, indicating a selective central mechanism. Chemical sympathectomy reduces Nebidrazine's cardiovascular effects more than clonidine's, and metiamide diminishes responses to both drugs, implicating central histamine receptors. These findings highlight Nebidrazine's distinct pharmacological profile and potential therapeutic application in managing hypertension through central alpha-autoreceptor stimulation .
Cat. No.: HY-16958R
CAS No.: 72596-74-8
Research Areas:
Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .
Cat. No.: HY-178471
CAS No.: 2975215-64-4
Target:
Research Areas:
FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (HY-D1056) (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD50 > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases .
Cat. No.: HY-181887
CAS No.: 3109883-60-2
Target:
Research Areas:
Nrf2 activator-23 is an orally active Keap1 binder and Nrf2 activator, with KD values of 28.68 nM and 54.55 nM for Keap1 and its Kelch domain, respectively. Nrf2 activator-23 disrupts the Keap1-Nrf2 interaction, reduces ubiquitination and degradation of Nrf2, and activates the Nrf2 signaling pathway. Nrf2 activator-23 inhibits RANKL-induced osteoclast formation, bone resorptive activity, ROS production, and activation of the MAPK and NF-κB signaling pathways, while downregulating the expression of osteoclast-specific genes and proteins. Nrf2 activator-23 attenuates bone loss and reduces osteoclast formation in vivo without affecting osteoblast differentiation and mineralization. Nrf2 activator-23 can be used for the research of osteoporosis .
Cat. No.: HY-181889
KRAS G12C-IN-75 is an orally active, blood-brain barrier penetrant KRAS G12C inhibitor with an IC50 of 0.53 nM. KRAS G12C-IN-75 attenuates active transport mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). KRAS G12C-IN-75 inhibits tumor growth, regulates the expression of downstream MAPK target genes DUSP6 and SPRY4, and exhibits dose-dependent KRAS G12C alkylation in KRAS G12C-positive xenograft models. KRAS G12C-IN-75 can be used for research related to non-small cell lung cancer .
Cat. No.: HY-182945
Research Areas:
IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma .
Cat. No.: HY-184897
CAS No.: 312724-83-7
Target:
Research Areas:
YS-01 is an inhibitor of pendrin (SLC26A4) with pulmonary protective activity. YS-01 inhibits pendrin-mediated anion exchange activity, reduces pendrin expression, and suppresses the activation of NF-κB and the production of proinflammatory cytokines. YS-01 alleviates lipopolysaccharide-induced and ventilator-induced lung injury. YS-01 attenuates ovalbumin-induced airway hyperresponsiveness, inflammatory infiltration, epithelial thickening and goblet cell hyperplasia, and reduces eosinophil and neutrophil counts. YS-01 decreases MUC5AC transcription levels induced by IL-4, reverses the reduction of airway surface liquid volume, and inhibits the increase of apical SCN − concentration in epithelial cells. YS-01 can be used in studies related to lung injury and allergic asthma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
